Latest news

Nanologica upptar lån om 20 MSEK inom avtalad kreditfacilitet

25 April, 2022

Nanologica AB (publ) har upptagit ett lån om 20 MSEK ur den kreditfacilitet som i januari avtalades med Flerie Invest AB. Lånet upptas i syfte att överbrygga bolagets tillfälliga finansiella behov i väntan på förväntade kassaflöden från verksamheten inom preparativ kromatografi. Efter lånet återstår 20 MSEK av kreditfaciliteten. För ytterligare information, vänligen kontakta: Johanna Johansson, Director IR, Communications and Marketing Tel: +46 72 211 21 90 eller e-post: ir@nanologica.com Om Nanologica AB (publ) Nanologica tillverkar,

Nanologica Expands Launch Road Show after Good Reception

12 April, 2022

After a successful first activity of the global launch of the company’s silica for preparative chromatography, NLAB Saga®, Nanologica expands the road show with participation at additional chromatography conferences. The launch of Nanologica’s silica for preparative chromatography started at the Purify’22 Chromatography Purification Conclave on April 7 in Hyderabad, India, where the products received a very good reception. In light of this, Nanologica has expanded its road show with additional conferences for chromatography. The company

Nanologica utökar lanseringsturné efter mycket gott mottagande

12 April, 2022

Efter en lyckad första aktivitet på den globala lanseringsturnén av bolagets silika för preparativ kromatografi, NLAB Saga®, utökar Nanologica turnén med deltagande vid ytterligare kromatografikonferenser. Lanseringen av bolagets silika för preparativ kromatografi startade på konferensen Purify’22 Chromatography Purification Conclave den 7 april i Hyderabad, Indien, där produkterna fick ett mycket gott mottagande. Nanologica har mot bakgrund av detta utökat sin lanseringsturné med ytterligare konferenser för kromatografi. Bolaget planerar att delta vid följande konferenser under 2022:

Nanologica to Attend Conferences in Preparative Chromatography

31 March, 2022

Nanologica will be attending several chromatography conferences during the spring in connection to the launch of the company’s silica for preparative chromatography, NLAB Saga®. The road show starts on April 7 at Purify’22 Chromatography Purification Conclave in Hyderabad, India, where Nanologica’s CEO Andreas Bhagwani will give the inaugural address on Pharmaceutical Megatrends and the Fundamental Impact of Chromatography, and where Nanologica’s SVP Chromatography Katarina Alenäs will give a talk on New Generation Silica for Peptide

Nanologica deltar i konferenser för preparativ kromatografi

31 March, 2022

Nanologica kommer att delta i flera kromatografikonferenser under våren i samband med lanseringen av bolagets silika för preparativ kromatografi, NLAB Saga®. Första konferensen är Purify’22 Chromatography Purification Conclave den 7 april i Hyderabad, Indien, där Nanologicas vd Andreas Bhagwani håller invigningstalet Pharmaceutical Megatrends and the Fundamental Impact of Chromatography och där Nanologicas SVP Chromatography Katarina Alenäs kommer att hålla ett föredrag om New Generation Silica for Peptide Purification. I maj deltar Nanologica på två konferenser

Trading in Nanologica’s shares on Nasdaq Stockholm commences today

29 March, 2022

Nanologica AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm’s main market today. “Nanologica is about to launch a world-class product within chromatography that can cut costs for insulin manufacturers, which may enable treatment for more diabetes patients. At the same time, we are progressing our unique platform for local delivery of drugs to the lung through internal development, with the goal of giving patients with severe lung diseases access

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Categories

News archive